Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a
-
Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a
Drug assessment at a glance
-
Drug assessment at a glance
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1 aged 3 years and older
Added benefit not proven
Project details
- Project no.
- A25-146
- Commission
- Commission awarded on 17.11.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A25-146
Connected Projects
-
Dossier assessment
Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed